Further, a clinical study has demonstrated that the combination of GLP-1R agonist and sodium–glucose cotransporter 2 (SGLT2) inhibitors significantly reduces the risk of all cause-mortality and improves renal function, compared to GLP-1R agonist alone in type 2 diabetic patients [69]. Here, SLC5A2 is linked to type 2 diabetes mellitus.